Mirae Asset Global Investments Co. Ltd. Reduces Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Mirae Asset Global Investments Co. Ltd. cut its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 5.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,687 shares of the company’s stock after selling 1,540 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.05% of Viridian Therapeutics worth $603,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Knights of Columbus Asset Advisors LLC increased its holdings in Viridian Therapeutics by 2.9% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 29,553 shares of the company’s stock worth $453,000 after purchasing an additional 823 shares during the last quarter. Silverarc Capital Management LLC grew its position in shares of Viridian Therapeutics by 5.4% in the 3rd quarter. Silverarc Capital Management LLC now owns 47,438 shares of the company’s stock worth $728,000 after acquiring an additional 2,438 shares in the last quarter. Swiss National Bank grew its position in shares of Viridian Therapeutics by 9.4% in the 3rd quarter. Swiss National Bank now owns 66,400 shares of the company’s stock worth $1,019,000 after acquiring an additional 5,700 shares in the last quarter. Raymond James & Associates grew its position in shares of Viridian Therapeutics by 71.1% in the 3rd quarter. Raymond James & Associates now owns 15,164 shares of the company’s stock worth $233,000 after acquiring an additional 6,303 shares in the last quarter. Finally, Eagle Asset Management Inc. grew its position in shares of Viridian Therapeutics by 1.9% in the 3rd quarter. Eagle Asset Management Inc. now owns 459,169 shares of the company’s stock worth $7,044,000 after acquiring an additional 8,731 shares in the last quarter.

Viridian Therapeutics Trading Down 2.5 %

NASDAQ:VRDN opened at $12.70 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.26 and a quick ratio of 18.26. Viridian Therapeutics, Inc. has a 12-month low of $10.93 and a 12-month high of $28.99. The business has a 50 day simple moving average of $17.29 and a 200 day simple moving average of $17.49. The firm has a market capitalization of $797.18 million, a P/E ratio of -2.39 and a beta of 1.07.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.37). Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.15 million. During the same quarter last year, the firm posted ($1.13) EPS. The company’s revenue was down 31.4% compared to the same quarter last year. Equities research analysts predict that Viridian Therapeutics, Inc. will post -4.39 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. B. Riley decreased their target price on Viridian Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. Wedbush lifted their target price on Viridian Therapeutics from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $36.60.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.